Global Stock Analysis

GBT
 Stock
  

USD 66.60  2.76  4.32%   

The newest price gain of Global Blood may raise some interest from private investors. The stock closed today at a share price of 66.60 on 39,307,678 in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.59. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Global Blood Ther partners.
Please check Risk vs Return Analysis.
  
The Global Blood stock analysis report makes it easy to digest most publicly released information about Global Blood and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Global Stock analysis module also helps to analyze the Global Blood price relationship with some important fundamental indicators such as market cap and management efficiency.

Global Stock Analysis Notes

About 117.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.86. Global Blood Ther had not issued any dividends in recent years. Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease . Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California. Global Blood operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 457 people. To learn more about Global Blood Ther call Ted Love at 650 741-7700 or check out www.globalbloodtx.com.

Global Blood Quarterly Cost of Revenue

1.05 Million

Global Blood Ther Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Global Blood's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Global Blood Ther or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Global Blood Ther is way too risky over 90 days horizon
Global Blood Ther appears to be risky and price may revert if volatility continues
The company reported the last year's revenue of 210.87 M. Reported Net Loss for the year was (309.58 M) with profit before taxes, overhead, and interest of 191.43 M.
Global Blood Ther has about 553.42 M in cash with (249.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.5.
Latest headline from www.marketwatch.com: Pfizer agrees to buy Global Blood Therapeutics in deal valued at 5.4 billion WSJ - MarketWatch

Global Blood Ther Upcoming and Recent Events

Earnings reports are used by Global Blood to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Global Blood previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Global Blood SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Global Blood prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Global Blood investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Global Blood Ther specific information freely available to individual and institutional investors to make a timely investment decision.
26th of July 2022
Financial Statements and Exhibits. Other Events
View
14th of July 2022
Financial Statements and Exhibits. Other Events
View
29th of June 2022
Financial Statements and Exhibits. Other Events
View
17th of June 2022
Unclassified Corporate Event
View
15th of June 2022
Submission of Matters to a Vote of Security Holders
View
13th of June 2022
Financial Statements and Exhibits. Other Events
View
10th of June 2022
Financial Statements and Exhibits. Other Events
View
6th of June 2022
Financial Statements and Exhibits. Other Events
View

Global Blood Thematic Classifications

In addition to having Global Blood stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French
Biotech
Biotechnology and pharmaceuticals production and services

Global Market Capitalization

The company currently falls under 'Mid-Cap' category with total capitalization of 4.16 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Global Blood's market, we take the total number of its shares issued and multiply it by Global Blood's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Global Profitablity

Global Blood's profitability indicators refer to fundamental financial ratios that showcase Global Blood's ability to generate income relative to its revenue or operating costs. If, let's say, Global Blood is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Global Blood's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Global Blood's profitability requires more research than a typical breakdown of Global Blood's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of (146.82) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (134.48) %, which entails that for every $100 of revenue, it lost -1.34.
Last ReportedProjected for 2022
Return on Investment(42.88) (46.26) 
Return on Average Assets(0.43) (0.46) 
Return on Average Equity(1.02) (1.11) 
Return on Invested Capital(0.60) (0.61) 
Return on Sales(1.47) (1.59) 

Management Efficiency

The entity has Return on Asset of (23.82) % which means that on every $100 spent on asset, it lost $23.82. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (124.53) %, meaning that it generated no profit with money invested by stockholders. Global Blood management efficiency ratios could be used to measure how well global blood ther manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -46.26 in 2022. Return on Average Assets is likely to drop to -0.46 in 2022. Global Blood Total Liabilities is comparatively stable at the moment as compared to the past year. Global Blood reported Total Liabilities of 742.8 Million in 2021. Liabilities Non Current is likely to gain to about 706.5 M in 2022, whereas Current Liabilities is likely to drop slightly above 69.9 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 3.12  3.50 
Enterprise Value over EBIT(6.00) (6.47) 
Enterprise Value over EBITDA(6.21) (6.71) 
Price to Book Value 9.60  8.64 
Tangible Assets Book Value per Share 14.92  13.76 
Enterprise Value1.7 BB
Tangible Asset Value939.2 M772.5 M

Technical Drivers

As of the 8th of August, Global Blood retains the Downside Deviation of 4.59, market risk adjusted performance of 0.9397, and Risk Adjusted Performance of 0.2394. Global Blood technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have analyzed nineteen technical drivers for Global Blood Ther, which can be compared to its competitors. Please check out Global Blood Ther standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Global Blood is priced fairly, providing market reflects its last-minute price of 66.6 per share. Given that Global Blood Ther has jensen alpha of 1.44, we strongly advise you to confirm Global Blood Ther's regular market performance to make sure the company can sustain itself at a future point.

Global Blood Ther Price Movement Analysis

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Triangular Moving Average shows Global Blood double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
.

Global Blood Ther Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Global Blood insiders, such as employees or executives, is commonly permitted as long as it does not rely on Global Blood's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Global Blood insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dawn Svoronos over a month ago via Macroaxis 
Sale by Dawn Svoronos of 1908 shares of Global Blood
Thompson Alexis A over a month ago via Macroaxis 
Acquisition by Thompson Alexis A of 3600 shares of Global Blood subject to Rule 16b-3
Smithwhitley Kim over two months ago via Macroaxis 
Exercise or conversion by Smithwhitley Kim of 6040 shares of Global Blood subject to Rule 16b-3
Habibizad Nazila over three months ago via Macroaxis 
Exercise or conversion by Habibizad Nazila of 183 shares of Global Blood subject to Rule 16b-3
Habibizad Nazila over three months ago via Macroaxis 
Payment of 540 shares by Habibizad Nazila of Global Blood subject to Rule 16b-3
Thompson Alexis A over three months ago via Macroaxis 
Exercise or conversion by Thompson Alexis A of 2400 shares of Global Blood subject to Rule 16b-3
Habibizad Nazila over three months ago via Macroaxis 
Acquisition by Habibizad Nazila of 28628 shares of Global Blood subject to Rule 16b-3
Habibizad Nazila over three months ago via Macroaxis 
Exercise or conversion by Habibizad Nazila of 1671 shares of Global Blood subject to Rule 16b-3
David Johnson over six months ago via Macroaxis 
Exercise or conversion by David Johnson of 3645 shares of Global Blood subject to Rule 16b-3
Ted Love over six months ago via Macroaxis 
Disposition of 24821 shares by Ted Love of Global Blood subject to Rule 16b-3
David Johnson over six months ago via Macroaxis 
Exercise or conversion by David Johnson of 4375 shares of Global Blood subject to Rule 16b-3
David Johnson over six months ago via Macroaxis 
Exercise or conversion by David Johnson of 3645 shares of Global Blood subject to Rule 16b-3

Global Blood Technical and Predictive Indicators

Global Blood Forecast Models

Global Blood time-series forecasting models is one of many Global Blood's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Global Blood's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Global Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Global Blood stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Global shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Global Blood. By using and applying Global Stock analysis, traders can create a robust methodology for identifying Global entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(1.43) (1.54) 
Gross Margin 0.98  1.09 
Profit Margin(1.56) (1.68) 
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease . Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California. Global Blood operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 457 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Global Blood to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Piotroski F Score Now

   

Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
All  Next Launch Module
Please check Risk vs Return Analysis. Note that the Global Blood Ther information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Global Stock analysis

When running Global Blood Ther price analysis, check to measure Global Blood's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Global Blood is operating at the current time. Most of Global Blood's value examination focuses on studying past and present price action to predict the probability of Global Blood's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Global Blood's price. Additionally, you may evaluate how the addition of Global Blood to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Global Blood's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Global Blood. If investors know Global will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Global Blood listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Global Blood Ther is measured differently than its book value, which is the value of Global that is recorded on the company's balance sheet. Investors also form their own opinion of Global Blood's value that differs from its market value or its book value, called intrinsic value, which is Global Blood's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Global Blood's market value can be influenced by many factors that don't directly affect Global Blood's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Global Blood's value and its price as these two are different measures arrived at by different means. Investors typically determine Global Blood value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Global Blood's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.